Elahere, validated in a phase 3 trial, is FDA-approved and offers the first major advancement for platinum-resistant ovarian cancer in decades.
Dr. Ryan Kahn
Advertisement
Articles by Dr. Ryan Kahn
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Areola Tattooing Helped Stephanie Wachtel Reclaim Confidence After Cancer
2
Keytruda Combo Improves Progression, Survival in Recurrent Ovarian Cancer
3
Postsurgical Opdivo Associated With Long-Term Activity in Melanoma
4
Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast Cancer
5
